Probable case of torsades de pointes induced by fluconazole

Pharmacotherapy

Volumn 22, Issue 12 I, 2002, Pages 1632-1637

  Khazan, Minou ^a   Mathis, A Scott ^a,b  

^a SAINT BARNABAS MEDICAL CENTER   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMIODARONE; ANTIARRHYTHMIC AGENT; CAPTOPRIL; CASPOFUNGIN; CEFTRIAXONE; FENTANYL; FLUCONAZOLE; FUROSEMIDE; GENTAMICIN; LIDOCAINE; MILRINONE; NAFCILLIN; NORADRENALIN; OMEPRAZOLE; VASOPRESSIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; ELECTROCARDIOGRAM; ENDOCARDITIS; FEMALE; FUNGEMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE PACING; HUMAN; QT INTERVAL; TORSADE DES POINTES;

EID: 0036896408     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.17.1632.34129     Document Type: Article

References (25)

1. Bauman JL, Bauernfeind RA, Hoff JV, Strasberg B, Swiryn S, Rosen KM. Torsades de pointes due to quinidine: Observations in 31 patients. Am Heart J 1984;107:425-30.
2. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Eur Heart J 2000;21:1216-31.
3. Terrell CL. Antifungal agents: Part II: The azoles. Mayo Clin Proc 1999;74:78-100.
4. Wassmann S, Nickenig G, Bohm M. Long QT syndrome and torsades de pointes in a patient receiving fluconazole [letter]. Ann Intern Med 1999;131:797.
5. Dorsey ST, Biblo LA. Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. Am J Emerg Med 2000;18:227-30.
6. Tholakanahalli VN, Hanley JF, Merliss AD. Fluconazole-induced torsades de pointes. Ann Pharmacother 2001;35: 432-4.
7. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
8. Anaissie EJ, Kontoyiannis DP, Huls C, et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 1995;172:599-602.
9. Kay GN, Plumb VJ, Archiniegas JG, Henthorn RW, Waldo AL. Torsades de pointes: The long-short initiating sequence and other clinical features: Observations in 32 patients. J Am Coll Cardiol 1983;2:806-17.
10. Roden DM. Taking the "idio" out of "idiosyncratic": Predicting torsades de pointes. PACE 1998;21:1029-34.
11. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270: 2590-7.
12. Bednar MM, Harrigan EP, Ruskin JN. Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol 2002;89:1316-19.
13. + channel by the antidepressant drug amitriptyline. Br J Pharmacol 2000;129:1474-80.
14. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects: A review with special reference to torsades de pointes tachycardia. Ann Int Med 1994;121:529-35.
15. Drouin E, Lande G, Charpentier F. Amiodarone reduces transmural heterogeneity of repolarization in the human heart. J Am Coll Cardiol 1998;32:1063-7.
16. Kr. Implications for torsades de pointes and reverse use-dependence. Circulation 1996;93:407-11.
17. Dumaine R, Roy M-L, Brown AM. Blockade of HERG and Kv1.5 by ketoconazole. J Pharmacol Exp Ther 1998;286: 727-35.
18. Paserchia LA, Hewett J, Woosley RL. Effects of ketoconazole on QTc [abstr]. Clin Pharmacol Ther 1994;55:146.
19. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 2000;97:12329-33.
20. Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmias. Proc Natl Acad Sci USA 2000;97:10613-18.
21. Khan IA. Clinical and therapeutic aspects of congenital and acquired long QT syndrome. Am J Med 2002;112:58-66.
22. Mauro VF, Bingle JF, Ginn SM, Jafri FM. Torsades de pointes in a patient receiving intravenous vasopressin. Crit Care Med 1988;16:200-1.
23. Tisdale JE, Patel RV, Webb CR, Borzak S, Zarowitz BJ. Proarrhythmic effects of intravenous vasopressors. Ann Pharmacother 1995;29:269-81.
24. Ackerman MJ, Khositseth A, Tester DJ, Hejlik JB, Shen W-K, Porter C-BJ. Epinephrine-induced QT interval prolongation: A gene specific paradoxical response in congenital long QT syndrome. Mayo Clin Proc 2002;77:413-21.
25. Pfizer Pharmaceutical Company. Diflucan (Fluconazole) Package Insert. New York, NY; 1998.